LRMR News and Press, Larimar Therapeutics Inc.

2026-06-30 08:50:28 ET Thesis As you know, Larimar Therapeutics ( LRMR ) has now formally initiated a rolling BLA submission with the FDA for nomlabofusp. We have support from notably constructive pre-BLA feedback, in which the agency indicated the existing dataset is actually suffi...

2026-06-29 13:52:09 ET Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia June 29, 2026 7:45 AM EDT... Read the full article on Seeking Alpha For further details see: Larimar Therapeutics, Inc. (LRMR) Dis...

FDA alignment on submission of BLA data package in multi-disciplinary Type B pre-BLA meeting minutes; first module of rolling BLA submitted with remaining modules expected 2H 2026 Daily nomlabofusp increased and sustained skin FXN levels at 1 year and 18 months; 100% (9/9) of participants ach...

Webcast on Monday, June 29, 2026, at 7:45 am ET BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will h...

2026-05-14 07:08:39 ET More on Larimar Therapeutics Larimar Therapeutics stock dips after pricing $100M share offering Larimar Therapeutics launches proposed $75 million public offering Seeking Alpha’s Quant Rating on Larimar Therapeutics Historical ea...

Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of 2026  Cross-species nonclinical findings that support skin frataxin levels...

BALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the publication entitled “Nomlabofusp Treatment Produces Frataxin Lev...

2026-03-22 18:37:56 ET Larimar Therapeutics, Inc. (LRMR) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 6.12%. The average open to low on the day of earnings was -6.57%. The average ope...

2026-03-22 18:32:57 ET Larimar Therapeutics, Inc. (LRMR) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in LRMR stock price following earnings has averaged ±4.14% , with a median of 2.25...

2026-03-19 07:21:41 ET More on Larimar Therapeutics Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Larimar Therapeutics, Inc. (LRMR) Pr...